I am writing on behalf of MSF to express our disappointment that J&J has not yet placed any patent into the Medicines Patent Pool and that it has announced in a recent letter to the Medicines Patent Pool that it is not ready to engage in formal negotiations.

More >

NY Times Lettter-to-the-Editor on MSF concerns that a provision in proposed U.S. health care legislation will allow pharmaceutical companies to extend monopolies on high-priced, cutting-edge medicines.

More >

MSF testified at a hearing before the US Trade Representative about the effect of US trade and intellectual property pressures on global health policy and efforts to expand access to affordable medicines in developing countries.

More >